FairValu
ABBOTT LABORATORIES

ABBOTT LABORATORIES

ABTNYSE

Medical Devices • Healthcare

Current Price
$112.470.00%
Market Cap
$194.62B
Shares Outstanding: 1.73B
Volume
-
Avg Vol (3M): -
Next Earnings
-
52 Week Range
Low: $--High: $--

Comprehensive AI Analysis

Strategic AI Analysis for ABT

Checking whether the approved providers contain enough current financial data for a reliable report.

Summary

Source-linked company research for ABT

Factor Scorecard

Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.

22/31 signals active· low confidence at 70% coverage
Overall Factor Score
5655-69 band
Growth
4240-54 band
Quality
7270-84 band
Valuation
4340-54 band
Financial Health
6655-69 band

Latest results at a glance

Insights from the latest company results and reports · filed 16 Jul 2026

  • Quarterly Earnings Performance

    Second-quarter GAAP diluted EPS was $0.53, while adjusted diluted EPS, which excludes specified items, was $1.31.

  • Earnings Exceed Consensus

    Reported EPS of $1.31 per share for the quarter ended June 30, 2026, exceeded the same-quarter consensus estimate of $1.28 per share.

  • Full-Year Guidance Raised

    Abbott raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, up from the previous range of $5.38 to $5.58.

  • Recent Product Partnership

    [2026-08-21] MiniMed Group announced that its MiniMed Flex system is commercially shipping in the U.S. integrated with Abbott’s Instinct continuous glucose sensor.

AI-generated · updated 28 Aug 2026View source filing

Price Chart

NYSE:ABT via TradingView

Loading TradingView chart...

Overview

Quarterly income statement data isn't available for this company.

No Data

No annual financial data available.

Financial Fundamentals

Growth, quality, valuation, cash generation, and balance-sheet strength.

Sector: Healthcare

Growth

TTM revenue plus current, long-term, forward, and accelerating top-line trends.

Revenue
-
Revenue Growth
6.6%
Moderate
Revenue CAGR 3Y
-
Forward Revenue Growth
13.5%
Moderate
Revenue Acceleration
1.6%
Improving

Earnings

Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.

EPS (TTM)
3.63
Profitable
EPS Growth
-53.5%
Declining
EPS CAGR 3Y
-
EPS Surprise
2.6%
Beat
Forward EPS
5.52
Profitable
Fwd Revenue Growth
13.5%
Forward EPS Growth
9.9%
Moderate

Profitability

TTM margin and return metrics that reflect pricing power and business quality.

Gross Margin
56.3%
High
Operating Margin
17.1%
High
Net Margin
13.9%
High
ROE
12.1%
Good
ROIC
7.5%
Average

Cash Flow

TTM free cash flow, growth, margin, and operating-cash conversion quality.

Free Cash Flow
$7.38B
Positive
FCF Growth
10.8%
Moderate
FCF Margin
-
Cash Conversion
1.51x
Excellent

Valuation

Metrics ranked by issuer type, financial state, and input quality.

Established companyPrimary lens

Forward P/E

Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.

Forward P/EPrimary
20.38x
Typical
EV / EBITDASupporting
24.16x
High
EV / FCFSupporting
30.07x
High
Trailing P/ESupporting
31.01x
High

Financial Health

Latest-quarter liquidity and leverage checks plus TTM interest coverage.

Current Ratio
1.39x
Adequate
Quick Ratio
0.84x
Adequate
Debt / Equity
0.65x
Moderate
Interest Coverage
-

Shareholder Signals

Capital returns and dilution checks sourced from statements and insider filings.

Dividend Yield
2.2%
Moderate
Payout Ratio
66.7%
High
Buyback Yield
0.4%
Positive
Net Insider Buys
-6
Selling

Peer Comparison

TickerPrice
ABTABBOTT LABORATORIES
$112.47
Company Profile

About the Company

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Next Earnings Date

Oct 14, 2026

Loading latest news...